Leah R. Cann
Stock Analyst at Brookline Capital Markets
(0.32)
# 4,120
Out of 4,356 analysts
657
Total ratings
37.7%
Success rate
-3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leah R. Cann
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Maintained: Buy | $50 → $30 | $4.37 | +586.50% | 15 | Feb 23, 2026 | |
| MRNA Moderna | Reiterated: Buy | $198 | $47.19 | +319.58% | 87 | Sep 23, 2025 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $70 → $65 | $81.42 | -20.17% | 19 | Jul 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | n/a | $56.18 | - | 36 | Jun 26, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterated: Buy | $130 → $120 | $4.31 | n/a | 19 | Mar 25, 2025 | |
| MRKR Marker Therapeutics | Initiated Coverage: Buy | $4 | $1.57 | n/a | 2 | Feb 10, 2025 | |
| KURA Kura Oncology | Maintained: Buy | $36 → $40 | $10.20 | n/a | 57 | Jan 6, 2025 | |
| CRBU Caribou Biosciences | Maintained: Buy | $26 → $34 | $2.36 | n/a | 20 | Jan 6, 2025 | |
| EXEL Exelixis | Initiated Coverage: Buy | $40 | $50.48 | n/a | 47 | Dec 23, 2024 | |
| SYRS Syros Pharmaceuticals, Inc. | Downgraded: Hold | n/a | $0.0002 | n/a | 63 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.01 | n/a | 48 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $99 → $24 | $14.07 | n/a | 29 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 → $90 | $17.62 | n/a | 17 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.33 | n/a | 33 | Dec 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.60 | n/a | 26 | Dec 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $224 | $336.79 | n/a | 84 | Dec 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.46 | n/a | 17 | Dec 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $29.40 | n/a | 38 | Dec 3, 2018 |
C4 Therapeutics
Feb 23, 2026
Maintained: Buy
Price Target: $50 → $30
Current: $4.37
Upside: +586.50%
Moderna
Sep 23, 2025
Reiterated: Buy
Price Target: $198
Current: $47.19
Upside: +319.58%
Kymera Therapeutics
Jul 7, 2025
Maintained: Buy
Price Target: $70 → $65
Current: $81.42
Upside: -20.17%
CRISPR Therapeutics AG
Jun 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $56.18
Upside: -
X4 Pharmaceuticals
Mar 25, 2025
Reiterated: Buy
Price Target: $130 → $120
Current: $4.31
Upside: n/a
Marker Therapeutics
Feb 10, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $1.57
Upside: n/a
Kura Oncology
Jan 6, 2025
Maintained: Buy
Price Target: $36 → $40
Current: $10.20
Upside: n/a
Caribou Biosciences
Jan 6, 2025
Maintained: Buy
Price Target: $26 → $34
Current: $2.36
Upside: n/a
Exelixis
Dec 23, 2024
Initiated Coverage: Buy
Price Target: $40
Current: $50.48
Upside: n/a
Syros Pharmaceuticals, Inc.
Nov 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $0.0002
Upside: n/a
Jul 22, 2024
Downgraded: Hold
Price Target: n/a
Current: $1.01
Upside: n/a
Jun 26, 2024
Reiterated: Buy
Price Target: $99 → $24
Current: $14.07
Upside: n/a
Jul 21, 2020
Initiated Coverage: Buy
Price Target: $19 → $90
Current: $17.62
Upside: n/a
Dec 31, 2018
Rated: Hold
Price Target: n/a
Current: $4.33
Upside: n/a
Dec 31, 2018
Rated: Hold
Price Target: n/a
Current: $3.60
Upside: n/a
Dec 4, 2018
Rated: Buy
Price Target: $224
Current: $336.79
Upside: n/a
Dec 4, 2018
Maintained: Hold
Price Target: n/a
Current: $3.46
Upside: n/a
Dec 3, 2018
Rated: Hold
Price Target: n/a
Current: $29.40
Upside: n/a